NCT01647867已完成不适用
Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 2
- 主要终点
- Expression and localization of Met C-terminal active fragments in NSCLC
研究概览
简要总结
Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.
详细描述
- Patient information and collection of signed inform consent
- Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
- Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
- Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
- Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
- Selection of blocks of interest and preparation of tumor samples
- Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
- Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
- Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with non small cell lung cancer (NSCLC)
- •Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
- •Treatment naive patient for metastatic NSCLC
- •Patients with or without neoadjuvant therapy for localized NSCLC
- •Male or female patients aged ≥ 18 years
- •Patient registered with the social security system
- •Having signed a written Informed Consent
排除标准
- •Malignant tumors which are not carcinoma
- •Small-cell malignant tumors
- •Secondary bronchial lesions
- •Revision surgery
- •Pregnant or breastfeeding women
- •Patient under guardianship or tutorship
- •Previous cancer
研究组 & 干预措施
Met analysis
Experimental
Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
干预措施: Met analysis on tissue and blood (Other)
结局指标
主要结局
Expression and localization of Met C-terminal active fragments in NSCLC
时间窗: baseline
Western Blot and immunohistochemistry
次要结局
- Expression in plasma of N-terminal Met fragments(baseline)
- Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival(baseline)
- Evaluation of the activation of Met receptor(baseline)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected PatientsCovid19NCT04516850Ricardo Pereira Mestre400
已完成
1 期
A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor TypesSolid TumorsNCT02296879Young Suk Park16
已完成
1 期
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express MesothelinAdvanced Recurrent Malignant Peritoneal Epithelioid MesotheliomaAdvanced Recurrent Serous Ovarian CancerAdvanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)Advanced Recurrent Malignant Pleural Epithelioid MesotheliomaNCT03507452Bayer36
终止
1 期
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid TumorsAdvanced CancerNCT00606879SGX Pharmaceuticals, Inc.46
终止
1 期
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid TumorsAdvanced CancerNCT00607399SGX Pharmaceuticals, Inc.46